Neurogene (NGNE) Earnings Date & Reports

Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn todayâ€™s complexÂ devastating neurological diseases into treatable conditions... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

NGNE is expected to report earnings to fall 25.00% to -2 cents per share on November 14

Q3'23

Est.

$-0.03

Q2'23

Est.

$-0.04

Q1'23

Missed

by $0.04

Q4'22

Missed

by $0.05

Q3'22

Beat

by $0.06

The last earnings report on August 16 showed earnings per share of -3 cents, meeting the estimate of -3 cents. With 390.59K shares outstanding, the current market capitalization sits at 156.16M.

View a ticker or compare two or three

Compare

NGNE